(NASDAQ: PGEN) Precigen's forecast annual revenue growth rate of 136.85% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Precigen's revenue in 2026 is $31,595,000.On average, 5 Wall Street analysts forecast PGEN's revenue for 2026 to be $45,248,373,582, with the lowest PGEN revenue forecast at $41,052,239,347, and the highest PGEN revenue forecast at $49,337,554,522. On average, 5 Wall Street analysts forecast PGEN's revenue for 2027 to be $83,284,530,038, with the lowest PGEN revenue forecast at $71,936,785,544, and the highest PGEN revenue forecast at $100,397,057,078.
In 2028, PGEN is forecast to generate $159,103,720,154 in revenue, with the lowest revenue forecast at $152,864,778,004 and the highest revenue forecast at $163,784,709,322.